Lorraine Cancer Institute

What Lorraine Cancer Institute does

Lorraine Cancer Institute provides cancer diagnosis and treatment. In addition, they offer radiology, medical oncology, surgery, radiotherapy, hormone therapy, supportive care, breast disease, treatment for tumors, and prevention services. The company's contact modes are by mail, phone, and physical address.

Name

Lorraine Cancer Institute

Legal name

Institut de Cancérologie de Lorraine

Website

https://www.icl-lorraine.fr

Company type

Private

Founded year

1924

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Lorraine Cancer Institute offers treatment, research, and education in oncology.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223), Medical and Diagnostic Laboratories (62151), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Surgical Oncology (HLAKAFAG)

Keywords

• Cancer treatment services
• Oncology care hospital
• Radiotherapy services
• Clinical research oncology
• Supportive care services

Headquarters

HQ city

Vandoeuvre-lès-nancy

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Soins de cancérologie: L'ICL est un établissement de santé privé d'intérêt collectif (ESPIC) reconnu d'utilité publique. Il assure des missions de prévention, de recherche, d'enseignement et de soins. L'établissement perçoit des financements de l'Assurance Maladie pour les soins, avec possibilité de prise en charge à 100% pour les traitements anticancéreux.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

The Institut de Cancérologie de Lorraine (ICL) provides comprehensive cancer care, including medical oncology (chemotherapy, immunotherapy, hormone therapy, targeted therapies), radiotherapy (Truebeam, Cyberknife M6), surgical oncology, diagnostic and interventional medical imaging, and interdisciplinary supportive care (SISSPO). It also runs an ISO 9001-certified clinical research department with 141 active protocols, a certified tumor bank, and the ICLlearning continuing-education center, serving as the sole 100% oncology-dedicated hospital in the Lorraine region.

Product overview

The Institut de Cancérologie de Lorraine (ICL) is a comprehensive cancer institute providing 100% oncology care. Its unified product portfolio encompasses diagnostic, treatment, and research services delivered through specialized departments including medical oncology (chemotherapy, immunotherapy, hormone therapy, targeted therapies), surgical oncology, radiotherapy (Truebeam®, Cyberknife®), and medical imaging (MRI, mammography, CT, ultrasound, conventional radiology). The institute operates coordinated care pathways for breast cancer (Parcours Sein) and head/neck cancers (Parcours Tête et Cou), supported by an interdisciplinary supportive care service (SISSPO) and a centralized chemotherapy preparation unit processing 180 preparations daily. ICL also conducts clinical research through its ISO 9001-certified research department and provides oncology education via ICLlearning. Patient document exchange is handled through LIFEN platform integration.

Differentiator

Problem solved

Functional benefit

Brands

• ICLlearning: The institute's approved training center providing initial and continuing oncology education for medical and paramedical personnel

Products and services

• Département d'oncologie médicale
• Département de radiothérapie
• Service d'imagerie médicale
• Parcours coordonnés (Sein and Tête et Cou)
• SISSPO — Service Interdisciplinaire de Soins de Support pour les Patients en Oncologie
• Unité Centralisée de Préparation des Chimiothérapies (UCPC)
• Plateforme PRIMO
• Recherche clinique (Clinical Research)
• Tumorothèque (Tumor Bank)
• ICLlearning

Quantifiable outcome

• 16 999 patients pris en charge annuellement avec 4 797 nouveaux patients
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and secondary.

• Cancéropôle EstcoreStrategic or Co-development Partner · 1 January 2018L'ICL a été chargé début 2018 de la coordination d'un réseau thématique consacré à la biopsie liquide au sein du Cancéropôle Est regroupant les régions Grand Est et Bourgogne Franche Comté. Expertise internationale en diagnostic moléculaire.
• UnicancercoreStrategic or Co-development PartnerL'ICL est membre d'Unicancer, la fédération des Centres de lutte contre le cancer (CLCC) et réseau de 19 établissements de santé privés à but non lucratif spécialisés en cancérologie. Unicancer est le premier promoteur académique d'essais cliniques en oncologie à l'échelle européenne.
• CHRU de NancycoreStrategic or Co-development PartnerConvention avec l'Université de Lorraine et le CHRU de Nancy pour l'accueil d'universitaires et la formation initiale des étudiants en médecine, pharmacie et odontologie. Co-fondateur de l'Hôpital Virtuel de Lorraine. Partenariat pour le Parcours Sein permettant une prise en charge coordonnée et partagée avec le CHRU de Nancy et le CH de Lunéville.
• Université de LorrainecoreStrategic or Co-development PartnerConvention liant l'ICL à l'Université de Lorraine pour l'accueil d'universitaires et la formation initiale des étudiants en médecine, pharmacie et odontologie. Co-fondateur de l'Hôpital Virtuel de Lorraine.
• CH de LunévillesecondaryStrategic or Co-development PartnerPartenariat pour le Parcours Sein permettant une prise en charge coordonnée et partagée avec le CHRU de Nancy et le CH de Lunéville pour proposer aux femmes et aux hommes de toute la région une prise en charge adaptée.
• NEON (Réseau de Cancérologie du Grand Est)coreStrategic or Co-development PartnerL'ICL est référent régional en cancérologie et s'investit dans le Réseau de Cancérologie du Grand Est (NEON).
• Institut de Rééducation et de Réadaptation (IRR)secondaryTechnology or IntegrationLe recours à une expertise en médecine rééducative et réadaptative peut être organisé en lien avec l'Institut de Rééducation et de Réadaptation (IRR) pour la rééducation et réadaptation des patients.
• Ligue contre le cancersecondaryGTM or Marketing PartnerPartenariat avec la Ligue contre le cancer pour information, prévention, offre de soins de support, actions sociales et financement de la recherche. Des patients ressources parcours interviennent sur proposition des professionnels ou à demande.

Scale indicators9 records

Recent moves12 records

Expansion highlights10 records

Direct peers

• Gustave Roussy: France's largest and leading comprehensive cancer center (CLCC/Unicancer member), based in Villejuif. Direct peer offering the full diagnostic-to-research oncology stack (radiotherapy, surgery, early-phase trials) at greater scale, with comparable coordination pathways and Unicancer affiliation.
• Centre Léon Bérard: Lyon-based Unicancer CLCC providing comprehensive cancer treatment, research, and teaching. Direct peer with similar service mix (medical/surgical/radiotherapy oncology, clinical trials) and regional referral positioning, but in a larger and more economically dynamic catchment (Auvergne-Rhône-Alpes).
• Institut Curie: Paris-based Unicancer CLCC combining hospital care with a world-class research center. Direct peer in comprehensive oncology delivery, with particular depth in radiotherapy (historical pioneer) and translational research; larger scale and brand than ICL but same federated model.
• Institut Bergonié: Bordeaux-based Unicancer CLCC covering the Nouvelle-Aquitaine region. Direct peer offering medical/surgical/radiotherapy oncology with similar CLCC positioning, comparable scale, and parallel reliance on Unicancer federation infrastructure.
• Centre François Baclesse: Caen-based Unicancer CLCC serving Normandy. Direct peer with comparable outpatient oncology focus, UCPC-equivalent chemo preparation, and similar regional single-site economics. Often cited alongside ICL as a comparable mid-sized CLCC.
• Centre Paul Strauss: Strasbourg-based Unicancer CLCC serving the Alsace portion of Grand Est. Direct peer and most proximate geographic competitor, with overlapping catchment and parallel coordination pathways; particularly comparable in regional positioning.
• Centre Jean Perrin: Clermont-Ferrand-based Unicancer CLCC covering Auvergne. Direct peer of similar scale (~300–500 beds equivalent), offering the same medical oncology / radiotherapy / surgery / research stack under the same ESPIC governance.
• Institut du Cancer de Montpellier (ICM): Montpellier-based Unicancer CLCC. Direct peer operating comprehensive oncology services in a different regional catchment (Occitanie), useful as a benchmark for pathway design, ambulatory oncology ratios, and clinical research output per employee.

Others

• CHRU de Nancy: University hospital center co-located with ICL on the Brabois plateau. Not a direct competitor (provides general hospital services including some oncology) but a structural partner and partial competitor for cancer referrals, sharing PRIMO ambulatory platform and breast cancer pathway.
• Unicancer: Federation of the 18 French CLCCs (including ICL) — provides shared R&D, IT (Talentsoft, Qualios), procurement, and academic sponsorship for clinical trials. Peer here in the sense of ecosystem orchestrator rather than competitor; sets collective strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lorraine Cancer Institute